Siemens Healthineers radiation therapy unit Varian has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) for a new clinical trial evaluating its Flash therapy technology.
Building on clinical evidence from the initial FeAsibility Study of Flash therapy for the Treatment of Symptomatic Bone Metastases (FAST-01) clinical trial, FAST-02 will include bone metastases in the chest, according to Varian.
The trial, which will be conducted at Cincinnati Children's/UC Health Proton Therapy Center, is expected to enroll 10 patients with painful thoracic bone metastases. Led by principal investigator Dr. John Breneman, the researchers will assess treatment-related side effects and treatment efficacy, Varian said.
